We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+33.89%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$165M
AUM Growth
+$30.6M
Cap. Flow
+$8.38M
Cap. Flow %
5.07%
Top 10 Hldgs %
37.21%
Holding
97
New
34
Increased
10
Reduced
12
Closed
29

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$9.28M
2
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$4.89M
3
APGE icon
Apogee Therapeutics
APGE
+$3.6M
4
CVS icon
CVS Health
CVS
+$2.99M
5
AKRO
Akero Therapeutics
AKRO
+$2.84M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$2.99M
2
FULC icon
Fulcrum Therapeutics
FULC
+$2.5M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.49M
4
VSTM icon
Verastem
VSTM
+$2.49M
5
GERN icon
Geron
GERN
+$2.07M

Sector Composition

Rank Sector Weight
1 Healthcare 89.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMPS
76
Compass Pathways
CMPS
$1.53B
– –
-213,544
Closed -$598K
COR icon
77
CALL
Cencora
COR
$60.6B
– –
-6,000
Closed -$1.8M
CRNX icon
78
Crinetics Pharmaceuticals
CRNX
$8.84B
– –
-62,700
Closed -$1.8M
DYN icon
79
Dyne Therapeutics
DYN
$4.7B
– –
-195,933
Closed -$1.87M
ELDN icon
80
Eledon Pharmaceuticals
ELDN
$261M
– –
-114,145
Closed -$309K
ELEV
81
DELISTED
Elevation Oncology
ELEV
– –
-110,353
Closed -$40.5K
FULC icon
82
CALL
Fulcrum Therapeutics
FULC
$273M
– –
-20,000
Closed -$138K
GPCR icon
83
Structure Therapeutics
GPCR
$3.41B
– –
-53,744
Closed -$1.11M
LEGN icon
84
Legend Biotech
LEGN
$3.59B
– –
-29,100
Closed -$1.03M
MREO
85
PUT
Mereo BioPharma
MREO
$54.7M
– –
-14,600
Closed -$39.6K
NAMS icon
86
NewAmsterdam Pharma
NAMS
$3.25B
– –
-36,574
Closed -$662K
NKTR icon
87
CALL
Nektar Therapeutics
NKTR
$2.39B
– –
-75,000
Closed -$1.94M
OEF icon
88
PUT
iShares S&P 100 ETF
OEF
$20.1B
– –
-200,000
Closed -$7.35M
RARE icon
89
CALL
Ultragenyx Pharmaceutical
RARE
$2.45B
– –
-37,500
Closed -$1.36M
RGNX icon
90
Regenxbio
RGNX
$620M
– –
-226,060
Closed -$1.86M
SRRK icon
91
Scholar Rock
SRRK
$5.67B
– –
-84,339
Closed -$2.99M
TIL icon
92
Instil Bio
TIL
$48.3M
– –
-16,200
Closed -$337K
UNH icon
93
CALL
UnitedHealth
UNH
$376B
– –
-1,400
Closed -$437K
VSTM icon
94
Verastem
VSTM
$510M
– –
-599,900
Closed -$2.49M
YARW
95
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
– –
-4,179
Closed -$345K
1 2 3
4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
CA
Carson Advisory Athens, Georgia $193M AUM 14.52% 1-Year Est. Return

Exome Asset Management's Q3 2025 Portfolio in Review

As of Q3 2025, Exome Asset Management held 97 positions worth $165M, up 23% from $135M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Exome Asset Management deployed $8.38M of net new capital in Q3 2025, opening 34 new positions and adding to 10 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 178,084 shares worth $1.28M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 80% a quarter earlier.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $2.5M trimmed.

  • Exome Asset Management's largest Q3 2025 buy was MoonLake Immunotherapeutics: 178,084 shares worth $1.28M.
  • Exome Asset Management added most to Eli Lilly in Q3 2025, an estimated $2.37M increase.
  • Exome Asset Management's biggest Q3 2025 reduction was Fulcrum Therapeutics, cutting an estimated $2.5M.
  • Exome Asset Management fully exited Scholar Rock in Q3 2025, selling an estimated $2.99M.
  • Exome Asset Management's ten largest holdings make up 37% of its $165M portfolio in Q3 2025.
  • Exome Asset Management opened 34 new positions and closed 29 in Q3 2025.
  • Exome Asset Management's portfolio value rose 23% quarter-over-quarter to $165M.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.